2. Academic Validation
  3. REGN5093-M114: can an antibody-drug conjugate overcome the challenge of resistance to epidermal growth factor receptor and mesenchymal epithelial transition tyrosine kinase inhibitors in non-small cell lung cancer?

REGN5093-M114: can an antibody-drug conjugate overcome the challenge of resistance to epidermal growth factor receptor and mesenchymal epithelial transition tyrosine kinase inhibitors in non-small cell lung cancer?

  • Transl Lung Cancer Res. 2024 Aug 31;13(8):2082-2086. doi: 10.21037/tlcr-24-144.
Julie Dardare 1,  Andréa Witz 1 2,  Alexandre Harlé 1 2
Affiliations

Affiliations

  • 1 Service de Biopathologie, Institut de Cancérologie de Lorraine, Vandoeuvre-les-Nancy, France.
  • 2 Université de Lorraine, Centre National de la Recherche Scientifique (CNRS), Unité Mixte de Recherche (UMR) 7039 Centre de Recherche en Automatique de Nancy (CRAN), Nancy, France.
PMID: 39263036 DOI: 10.21037/tlcr-24-144
Keywords

Epidermal growth factor receptor (EGFR); REGN5093-M114; mesenchymal epithelial transition (MET); non-small cell lung cancer (NSCLC); resistance.

Figures
Products